Earnings summaries and quarterly performance for SYNLOGIC.
Executive leadership at SYNLOGIC.
Board of directors at SYNLOGIC.
Research analysts who have asked questions during SYNLOGIC earnings calls.
KN
Keay Nakae
Chardan Capital Markets
3 questions for SYBX
Also covers: ALUR, STEM
MB
Mark Breidenbach
Oppenheimer & Co. Inc.
2 questions for SYBX
Also covers: IMRX
Mitchell Kapoor
H.C. Wainwright & Co.
2 questions for SYBX
Also covers: CTMX, HALO, INM +7 more
J
Jacqueline
Oppenheimer & Co. Inc.
1 question for SYBX
Also covers: AZTA
JS
Joseph Schwartz
Oppenheimer
1 question for SYBX
Also covers: ASND, AUPH, BMRN +14 more
RS
Raghuram Selvaraju
H.C. Wainwright & Co.
1 question for SYBX
Also covers: ABEO, ACOG, AQST +20 more
Recent press releases and 8-K filings for SYBX.
Synbio International Inc. Acquires Equity Stake in FacialDx, Forms Joint Trial Committee
SYBX
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Synbio International Inc. (Synbio) has executed a Share Purchase Agreement (SPA) and Warrant Agreement with FacialDx, Inc., strengthening their strategic partnership.
- Under the SPA, Synbio will acquire 100,000 Class A common stock in FacialDx with US$200,000 in staged funding commitments over the next 12 months, and retains the right to convert up to US$2.5 million in future clinical trial expenditures into additional FacialDx shares upon FDA approval.
- A Joint Trial Committee will be established to oversee clinical studies, aiming to maximize the likelihood of FDA approval and successful commercialization of FacialDx's AI-powered facial analysis technology.
- FacialDx has the right to acquire 30,000,000 of Synbio's common stock at an exercise price of $0.001 per share upon FDA approval.
Oct 8, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more